ManagementManagementManagementManagement
  • OUR APPROACH
  • SCIENCE
  • PROGRAMS
  • TEAM
  • INVESTOR INFORMATION
  • About LIXTE
    • Management
    • Board of Directors
    • Forward-Looking Statements
  • Product Development
  • Publications
  • Investor Information
    • Investor Alerts
menu toggle
Close
Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity Matrix

Press Releases

  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Sep 26, 2023 8:30am EDT

LIXTE Appoints Bas van der Baan as President and Chief Executive Officer

Sep 20, 2023 8:30am EDT

LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer

Jul 20, 2023 4:05pm EDT

LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules

Jul 18, 2023 8:00am EDT

LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules

Jul 17, 2023 8:30am EDT

Preclinical Results of LIXTE Biotechnology’s Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE’s Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and Chemotherapy

Jun 23, 2023 8:30am EDT

LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirements

Jun 07, 2023 8:30am EDT

LIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b/2 Randomized Trial of Doxorubicin +/- LIXTE’s Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue Sarcomas

Jun 02, 2023 12:30pm EDT

LIXTE Biotechnology Holdings, Inc. Announces 1-for-10 Reverse Stock Split of its Common Stock Effective on Pre-Market Opening on June 5, 2023

May 30, 2023 8:30am EDT

Recently Published Independent Research Reveals New Mechanisms by Which LIXTE Biotechnology’s Lead Clinical Compound, LB-100, Increases Effectiveness of Cancer Immunotherapy

Apr 24, 2023 8:30am EDT

LIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b/2 Clinical Trial of LIXTE's Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue Sarcoma

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
RSS
  • Email Alerts
  • Contacts
  • RSS News Feed

Contact

LIXTE Biotechnology Holdings, Inc.
680 E Colorado Blvd., Suite 180
Pasadena, CA 91101

General Phone: (631) 830-7092
Investor Phone: (888) 289-5533
Fax: (631) 982-5050
info@lixte.com

LIXTE Biotechnology Holdings, Inc. is publicly traded as LIXT.

About LIXTE

  • About LIXTE
  • Management
  • Board of Directors
  • Forward-Looking Statements

Development

  • Product Development

Publications

  • Publications

Investor Information

  • Investor Information
  • Email Alerts
Back to top
© 2023 LIXTE Biotechnology Holdings, Inc. (LIXTE). All Rights Reserved. Site by Third Eye Industries
    Close